UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases

Nature communications, 2019-06, Vol.10 (1), p.2686-14, Article 2686

2019

Volltextzugriff (PDF)

Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial

The American journal of gastroenterology, 2023-01, Vol.118 (1), p.138-147

2023

Volltextzugriff (PDF)

Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects

Clinical and translational science, 2022-02, Vol.15 (2), p.361-370

2022

Volltextzugriff (PDF)

TrkC plays an essential role in breast tumor growth and metastasis

Carcinogenesis (New York), 2010-11, Vol.31 (11), p.1939-1947

2010

Volltextzugriff (PDF)

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial

Intestinal research, 2023, 21(1), , pp.110-125

2023

Volltextzugriff (PDF)

Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan: A Randomized, Open-label, 3-period, Multiple-dose Crossover Study in Healthy Korean Male Subjects

Clinical therapeutics, 2014-08, Vol.36 (8), p.1159-1170

2014

Volltextzugriff (PDF)

TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling

Cancer research (Chicago, Ill.), 2007-10, Vol.67 (20), p.9869-9877

2007

Volltextzugriff (PDF)

TRAF6 mediates IL-1β/LPS-induced suppression of TGF-β signaling through its interaction with the type III TGF-β receptor

PloS one, 2012-03, Vol.7 (3), p.e32705

2012

Volltextzugriff (PDF)

Pharmacokinetics of Rosuvastatin/Olmesartan Fixed-Dose Combination: A Single-Dose, Randomized, Open-Label, 2-Period Crossover Study in Healthy Korean Subjects

Clinical therapeutics, 2013-07, Vol.35 (7), p.915-922

2013

Volltextzugriff (PDF)

c-Src Is Required for Tropomyosin Receptor Kinase C (TrkC)-induced Activation of the Phosphatidylinositol 3-Kinase (PI3K)-AKT Pathway

The Journal of biological chemistry, 2008-01, Vol.283 (3), p.1391-1400

2008

Volltextzugriff (PDF)

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

The Lancet (British edition), 2021-06, Vol.397 (10292), p.2372-2384

2021

Volltextzugriff (PDF)

Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial

Annals of internal medicine, 2017-01, Vol.166 (2), p.109

2017

Volltextzugriff (PDF)

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

Journal of hepatology, 2017-05, Vol.66 (5), p.910-918

2017

Volltextzugriff (PDF)

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

Clinical infectious diseases, 2016-12, Vol.63 (11), p.1405-1411

2016

Volltextzugriff (PDF)

133 SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTIONLTE LONG-TERM EXTENSION STUDY

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-37-S-38

2021

Volltextzugriff (PDF)

Fr537 EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-352-S-353

2021

Volltextzugriff (PDF)

987 EFFICACY AND SAFETY OF THE ORAL SELECTIVE SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR MODULATOR VTX002 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-240-S-240

2024

Volltextzugriff (PDF)

Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV

Gastroenterology (New York, N.Y. 1943), 2018-03, Vol.154 (4), p.989-997

2018

Volltextzugriff (PDF)

PMO-30 Corticosteroid-free remission of ulcerative colitis with filgotinib maintenance therapy: post-hoc analysis of the SELECTION study

Gut, 2021-11, Vol.70 (Suppl 4), p.A92-A92

2021

Volltextzugriff (PDF)

OMO-3 Safety analysis of filgotinib for ulcerative colitis: Phase 2b/3 selection study and long-term extension results

Gut, 2021-11, Vol.70 (Suppl 4), p.A6-A6

2021

Volltextzugriff (PDF)

PMO-31 Rapidity of ulcerative colitis symptom improvements during filgotinib induction: phase 2b/3 SELECTION study post-hoc analysis

Gut, 2021-11, Vol.70 (Suppl 4), p.A93-A93

2021

Volltextzugriff (PDF)

Sa575 FILGOTINIB PROVIDES IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: SF-36 RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-558-S-558

2021

Volltextzugriff (PDF)

648 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-125-S-125

2021

Volltextzugriff (PDF)

Fr531 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-350-S-350

2021

Volltextzugriff (PDF)

Ledipasvir–sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial

The lancet. Gastroenterology & hepatology, 2017-05, Vol.2 (5), p.347-353

2017

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases

Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial

Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects

TrkC plays an essential role in breast tumor growth and metastasis

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial

Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan: A Randomized, Open-label, 3-period, Multiple-dose Crossover Study in Healthy Korean Male Subjects

TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling

TRAF6 mediates IL-1β/LPS-induced suppression of TGF-β signaling through its interaction with the type III TGF-β receptor

Pharmacokinetics of Rosuvastatin/Olmesartan Fixed-Dose Combination: A Single-Dose, Randomized, Open-Label, 2-Period Crossover Study in Healthy Korean Subjects

c-Src Is Required for Tropomyosin Receptor Kinase C (TrkC)-induced Activation of the Phosphatidylinositol 3-Kinase (PI3K)-AKT Pathway

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

133 SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTIONLTE LONG-TERM EXTENSION STUDY

Fr537 EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

987 EFFICACY AND SAFETY OF THE ORAL SELECTIVE SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR MODULATOR VTX002 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL

Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV

PMO-30 Corticosteroid-free remission of ulcerative colitis with filgotinib maintenance therapy: post-hoc analysis of the SELECTION study

OMO-3 Safety analysis of filgotinib for ulcerative colitis: Phase 2b/3 selection study and long-term extension results

PMO-31 Rapidity of ulcerative colitis symptom improvements during filgotinib induction: phase 2b/3 SELECTION study post-hoc analysis

Sa575 FILGOTINIB PROVIDES IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: SF-36 RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

648 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Fr531 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Ledipasvir–sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial

Suchergebnisse filtern